Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,654
archived clinical trials in
Cardiology

Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Status: Archived
833
mi
from
Tucson, AZ
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Status: Archived
Updated: 1/1/1970
Arizona Cancer Center, University of Arizona
833
mi
from
Tucson, AZ
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Status: Archived
1151
mi
from
Duarte, CA
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Status: Archived
Updated: 1/1/1970
City of Hope Medical Canter
1151
mi
from
Duarte, CA
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Status: Archived
1317
mi
from
Concord, CA
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Status: Archived
Updated: 1/1/1970
Bay Area Cancer Research Group
1317
mi
from
Concord, CA
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Status: Archived
1177
mi
from
Torrance, CA
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Status: Archived
Updated: 1/1/1970
Harbor-UCLA Med Ctr
1177
mi
from
Torrance, CA
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Status: Archived
1350
mi
from
Farmington, CT
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Status: Archived
Updated: 1/1/1970
University of Connecticut Health Center
1350
mi
from
Farmington, CT
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Status: Archived
1389
mi
from
Norwich, CT
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Status: Archived
Updated: 1/1/1970
Eastern Connecticut Hematology & Oncology
1389
mi
from
Norwich, CT
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Status: Archived
1125
mi
from
Washington,
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Status: Archived
Updated: 1/1/1970
Georgetown Univ Med Ctr
1125
mi
from
Washington,
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Status: Archived
1129
mi
from
Daytona Beach, FL
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Status: Archived
Updated: 1/1/1970
Halifax Health Medical Center
1129
mi
from
Daytona Beach, FL
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Status: Archived
805
mi
from
Decatur, GA
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Status: Archived
Updated: 1/1/1970
Atlanta Institute for Medical Research, Inc
805
mi
from
Decatur, GA
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Status: Archived
611
mi
from
Chicago, IL
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Status: Archived
Updated: 1/1/1970
Hematology and Oncology Associates of IL
611
mi
from
Chicago, IL
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Status: Archived
610
mi
from
Niles, IL
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Status: Archived
Updated: 1/1/1970
Orchard Health Care Research
610
mi
from
Niles, IL
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Status: Archived
657
mi
from
Louisville, KY
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Status: Archived
Updated: 1/1/1970
James Graham Brown Cancer Center
657
mi
from
Louisville, KY
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Status: Archived
1438
mi
from
Chestnut Hill, MA
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Status: Archived
Updated: 1/1/1970
Brigham & Women's Hospital Women's Health Center
1438
mi
from
Chestnut Hill, MA
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Status: Archived
841
mi
from
Detroit, MI
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Status: Archived
Updated: 1/1/1970
Henry Ford Hospital
841
mi
from
Detroit, MI
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Status: Archived
1121
mi
from
Rochester, NY
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Status: Archived
Updated: 1/1/1970
Strong Memorial Hospital (University of Rochester School of Medicine)
1121
mi
from
Rochester, NY
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Status: Archived
1358
mi
from
Stony Brook, NY
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Status: Archived
Updated: 1/1/1970
Stony Brook University Hospital and Medical Center
1358
mi
from
Stony Brook, NY
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Status: Archived
1052
mi
from
Durham, NC
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Status: Archived
Updated: 1/1/1970
Duke Univ Med Ctr
1052
mi
from
Durham, NC
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Status: Archived
510
mi
from
Normal, IL
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Status: Archived
Updated: 1/1/1970
Mid Illinois Hematology & Oncology
510
mi
from
Normal, IL
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Status: Archived
1226
mi
from
Philadelphia, PA
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Status: Archived
Updated: 1/1/1970
Pennsylvania Oncology Hematology Associates
1226
mi
from
Philadelphia, PA
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Status: Archived
1142
mi
from
Orlando, FL
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Status: Archived
Updated: 1/1/1970
M. D. Anderson Cancer Center
1142
mi
from
Orlando, FL
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Status: Archived
777
mi
from
Salt Lake City, UT
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Status: Archived
Updated: 1/1/1970
University of Utah
777
mi
from
Salt Lake City, UT
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Status: Archived
1356
mi
from
Burlington, VT
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Status: Archived
Updated: 1/1/1970
Fletcher Allen Health Care
1356
mi
from
Burlington, VT
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Status: Archived
1049
mi
from
Charlottesville, VA
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
Status: Archived
Updated: 1/1/1970
University of Virginia
1049
mi
from
Charlottesville, VA
The Effects of Inhaled Nitric Oxide After Fontan Operation
The Effects of Inhaled Nitric Oxide on Patient Morbidity and Length of Hospital Stay Following Fontan Operation
Status: Archived
1204
mi
from
Wilmington, DE
The Effects of Inhaled Nitric Oxide After Fontan Operation
The Effects of Inhaled Nitric Oxide on Patient Morbidity and Length of Hospital Stay Following Fontan Operation
Status: Archived
Updated: 1/1/1970
Alfred I. duPont Hospital for Children
1204
mi
from
Wilmington, DE
Heart Failure (HF) Assessment With B-type Natriuretic Peptide (BNP) In The Home
HF Assessment With BNP In The Home
Status: Archived
1097
mi
from
Banning, CA
Heart Failure (HF) Assessment With B-type Natriuretic Peptide (BNP) In The Home
HF Assessment With BNP In The Home
Status: Archived
Updated: 1/1/1970
Beaver Medical Group
1097
mi
from
Banning, CA
Heart Failure (HF) Assessment With B-type Natriuretic Peptide (BNP) In The Home
HF Assessment With BNP In The Home
Status: Archived
1145
mi
from
LaJolla, CA
Heart Failure (HF) Assessment With B-type Natriuretic Peptide (BNP) In The Home
HF Assessment With BNP In The Home
Status: Archived
Updated: 1/1/1970
Scripps HealthCare
1145
mi
from
LaJolla, CA
Heart Failure (HF) Assessment With B-type Natriuretic Peptide (BNP) In The Home
HF Assessment With BNP In The Home
Status: Archived
1114
mi
from
Loma Linda, CA
Heart Failure (HF) Assessment With B-type Natriuretic Peptide (BNP) In The Home
HF Assessment With BNP In The Home
Status: Archived
Updated: 1/1/1970
Loma Linda Medical Center
1114
mi
from
Loma Linda, CA
Heart Failure (HF) Assessment With B-type Natriuretic Peptide (BNP) In The Home
HF Assessment With BNP In The Home
Status: Archived
1028
mi
from
Loma Linda, CA
Heart Failure (HF) Assessment With B-type Natriuretic Peptide (BNP) In The Home
HF Assessment With BNP In The Home
Status: Archived
Updated: 1/1/1970
VA Medical Center, Loma Linda
1028
mi
from
Loma Linda, CA
Heart Failure (HF) Assessment With B-type Natriuretic Peptide (BNP) In The Home
HF Assessment With BNP In The Home
Status: Archived
1147
mi
from
Mission Viejo, CA
Heart Failure (HF) Assessment With B-type Natriuretic Peptide (BNP) In The Home
HF Assessment With BNP In The Home
Status: Archived
Updated: 1/1/1970
Mission Internal Medical Group
1147
mi
from
Mission Viejo, CA
Heart Failure (HF) Assessment With B-type Natriuretic Peptide (BNP) In The Home
HF Assessment With BNP In The Home
Status: Archived
1154
mi
from
Orange, CA
Heart Failure (HF) Assessment With B-type Natriuretic Peptide (BNP) In The Home
HF Assessment With BNP In The Home
Status: Archived
Updated: 1/1/1970
St. Josephs Hospital
1154
mi
from
Orange, CA
Heart Failure (HF) Assessment With B-type Natriuretic Peptide (BNP) In The Home
HF Assessment With BNP In The Home
Status: Archived
1153
mi
from
Orange, CA
Heart Failure (HF) Assessment With B-type Natriuretic Peptide (BNP) In The Home
HF Assessment With BNP In The Home
Status: Archived
Updated: 1/1/1970
University of California, Irvine Medical Center
1153
mi
from
Orange, CA
Heart Failure (HF) Assessment With B-type Natriuretic Peptide (BNP) In The Home
HF Assessment With BNP In The Home
Status: Archived
1081
mi
from
Palm Springs, CA
Heart Failure (HF) Assessment With B-type Natriuretic Peptide (BNP) In The Home
HF Assessment With BNP In The Home
Status: Archived
Updated: 1/1/1970
Comprehensive Cancer Center
1081
mi
from
Palm Springs, CA
Heart Failure (HF) Assessment With B-type Natriuretic Peptide (BNP) In The Home
HF Assessment With BNP In The Home
Status: Archived
1139
mi
from
San Diego, CA
Heart Failure (HF) Assessment With B-type Natriuretic Peptide (BNP) In The Home
HF Assessment With BNP In The Home
Status: Archived
Updated: 1/1/1970
San Diego Cardiac Center
1139
mi
from
San Diego, CA
Heart Failure (HF) Assessment With B-type Natriuretic Peptide (BNP) In The Home
HF Assessment With BNP In The Home
Status: Archived
1060
mi
from
Buffalo, NY
Heart Failure (HF) Assessment With B-type Natriuretic Peptide (BNP) In The Home
HF Assessment With BNP In The Home
Status: Archived
Updated: 1/1/1970
VA Western New York Healthcare System, Buffalo, NY
1060
mi
from
Buffalo, NY
Heart Failure (HF) Assessment With B-type Natriuretic Peptide (BNP) In The Home
HF Assessment With BNP In The Home
Status: Archived
1166
mi
from
Los Angeles, CA
Heart Failure (HF) Assessment With B-type Natriuretic Peptide (BNP) In The Home
HF Assessment With BNP In The Home
Status: Archived
Updated: 1/1/1970
University of Southern California Women's and Children's Hospital
1166
mi
from
Los Angeles, CA
Investigation of the Biomarker Copeptin in Patients With Acute Myocardial Infarction
Copeptin Helps in the Early Detection Of Patients With Acute Myocardial
Status: Archived
1329
mi
from
Stanford, CA
Investigation of the Biomarker Copeptin in Patients With Acute Myocardial Infarction
Copeptin Helps in the Early Detection Of Patients With Acute Myocardial
Status: Archived
Updated: 1/1/1970
Stanford university Hospital and Clinics
1329
mi
from
Stanford, CA
Investigation of the Biomarker Copeptin in Patients With Acute Myocardial Infarction
Copeptin Helps in the Early Detection Of Patients With Acute Myocardial
Status: Archived
1339
mi
from
San Francisco, CA
Investigation of the Biomarker Copeptin in Patients With Acute Myocardial Infarction
Copeptin Helps in the Early Detection Of Patients With Acute Myocardial
Status: Archived
Updated: 1/1/1970
San Francisco General Hospital
1339
mi
from
San Francisco, CA
Investigation of the Biomarker Copeptin in Patients With Acute Myocardial Infarction
Copeptin Helps in the Early Detection Of Patients With Acute Myocardial
Status: Archived
1340
mi
from
San Francisco, CA
Investigation of the Biomarker Copeptin in Patients With Acute Myocardial Infarction
Copeptin Helps in the Early Detection Of Patients With Acute Myocardial
Status: Archived
Updated: 1/1/1970
Unversity of California, San Francisco
1340
mi
from
San Francisco, CA
Investigation of the Biomarker Copeptin in Patients With Acute Myocardial Infarction
Copeptin Helps in the Early Detection Of Patients With Acute Myocardial
Status: Archived
196
mi
from
Kansas City, KA
Investigation of the Biomarker Copeptin in Patients With Acute Myocardial Infarction
Copeptin Helps in the Early Detection Of Patients With Acute Myocardial
Status: Archived
Updated: 1/1/1970
Kansas University Medical Center
196
mi
from
Kansas City, KA
Investigation of the Biomarker Copeptin in Patients With Acute Myocardial Infarction
Copeptin Helps in the Early Detection Of Patients With Acute Myocardial
Status: Archived
1148
mi
from
Baltimore, MD
Investigation of the Biomarker Copeptin in Patients With Acute Myocardial Infarction
Copeptin Helps in the Early Detection Of Patients With Acute Myocardial
Status: Archived
Updated: 1/1/1970
University of Maryland, Baltimore
1148
mi
from
Baltimore, MD
Investigation of the Biomarker Copeptin in Patients With Acute Myocardial Infarction
Copeptin Helps in the Early Detection Of Patients With Acute Myocardial
Status: Archived
1443
mi
from
Boston, MA
Investigation of the Biomarker Copeptin in Patients With Acute Myocardial Infarction
Copeptin Helps in the Early Detection Of Patients With Acute Myocardial
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
1443
mi
from
Boston, MA
Investigation of the Biomarker Copeptin in Patients With Acute Myocardial Infarction
Copeptin Helps in the Early Detection Of Patients With Acute Myocardial
Status: Archived
841
mi
from
Detroit, MI
Investigation of the Biomarker Copeptin in Patients With Acute Myocardial Infarction
Copeptin Helps in the Early Detection Of Patients With Acute Myocardial
Status: Archived
Updated: 1/1/1970
Henry Ford Hospital
841
mi
from
Detroit, MI
Investigation of the Biomarker Copeptin in Patients With Acute Myocardial Infarction
Copeptin Helps in the Early Detection Of Patients With Acute Myocardial
Status: Archived
552
mi
from
Minneapolis, MN
Investigation of the Biomarker Copeptin in Patients With Acute Myocardial Infarction
Copeptin Helps in the Early Detection Of Patients With Acute Myocardial
Status: Archived
Updated: 1/1/1970
Hennepin County Medical Center - Minneapolis
552
mi
from
Minneapolis, MN
Investigation of the Biomarker Copeptin in Patients With Acute Myocardial Infarction
Copeptin Helps in the Early Detection Of Patients With Acute Myocardial
Status: Archived
898
mi
from
Cleveland, OH
Investigation of the Biomarker Copeptin in Patients With Acute Myocardial Infarction
Copeptin Helps in the Early Detection Of Patients With Acute Myocardial
Status: Archived
Updated: 1/1/1970
The Cleveland Clinic
898
mi
from
Cleveland, OH
Investigation of the Biomarker Copeptin in Patients With Acute Myocardial Infarction
Copeptin Helps in the Early Detection Of Patients With Acute Myocardial
Status: Archived
1223
mi
from
Philadelphia, PA
Investigation of the Biomarker Copeptin in Patients With Acute Myocardial Infarction
Copeptin Helps in the Early Detection Of Patients With Acute Myocardial
Status: Archived
Updated: 1/1/1970
Hospital of the University of Pennsylvania
1223
mi
from
Philadelphia, PA
Investigation of the Biomarker Copeptin in Patients With Acute Myocardial Infarction
Copeptin Helps in the Early Detection Of Patients With Acute Myocardial
Status: Archived
1113
mi
from
Richmond, VA
Investigation of the Biomarker Copeptin in Patients With Acute Myocardial Infarction
Copeptin Helps in the Early Detection Of Patients With Acute Myocardial
Status: Archived
Updated: 1/1/1970
VCU Medical Center
1113
mi
from
Richmond, VA
Study of Left Ventricular Dyssynchrony in Heart Failure Patients
Study of the Phenomenon of Dynamic Left Ventricular Dyssynchrony in Heart Failure Patients and Its Clinical Significance.
Status: Archived
1295
mi
from
Bronx, NY
Study of Left Ventricular Dyssynchrony in Heart Failure Patients
Study of the Phenomenon of Dynamic Left Ventricular Dyssynchrony in Heart Failure Patients and Its Clinical Significance.
Status: Archived
Updated: 1/1/1970
Albert Einstein College of Medicine
1295
mi
from
Bronx, NY
Evaluation of Endovenous Sclerotherapy for Treatment of Varicose Veins
Evaluation of Clinical Characteristics of Endovenous Sclerotherapy of Varicose Veins
Status: Archived
158
mi
from
Oklahoma City, OK
Evaluation of Endovenous Sclerotherapy for Treatment of Varicose Veins
Evaluation of Clinical Characteristics of Endovenous Sclerotherapy of Varicose Veins
Status: Archived
Updated: 1/1/1970
The University of Oklahoma Health Science Center
158
mi
from
Oklahoma City, OK
Evaluation of a Diagnostic Feature in a Cardiac Resynchronization Therapy (CRT) Device
Clinical Evaluation of the Physiological Diagnosis Function in the Paradym CRT Device
Status: Archived
841
mi
from
Mesa, AZ
Evaluation of a Diagnostic Feature in a Cardiac Resynchronization Therapy (CRT) Device
Clinical Evaluation of the Physiological Diagnosis Function in the Paradym CRT Device
Status: Archived
Updated: 1/1/1970
Mountain Vista Hospital
841
mi
from
Mesa, AZ
Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Uveitic Macular Edema
Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Uveitic Macular Edema
Status: Archived
1290
mi
from
New York, NY
Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Uveitic Macular Edema
Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Uveitic Macular Edema
Status: Archived
Updated: 1/1/1970
Department of Ophthalmology, Mount Sinai School of Medicine
1290
mi
from
New York, NY